 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 May 1997 | Volume 126 Issue 10 | Pages 791-798
The use of crude marijuana for herbal medicinal applications is now being widely discussed in both the medical and lay literature.Ballot initiatives in California and Arizona have recently made crude marijuana accessible to patients under certain circumstances. As medicinal applications of pure forms of delta-9-tetrahydrocannabinol (THC) and crude marijuana are being considered, the most promising uses of any form of THC are to counteract the nausea associated with cancer chemotherapy and to stimulate appetite.
We evaluated the relevant research published between 1975 and 1996 on the medical applications, physical complications, and legal precedents for the use of pure THC or crude marijuana.Our review focused on the medical use of THC derivatives for nausea associated with cancer chemotherapy, glaucoma, stimulation of appetite, and spinal cord spasticity. Despite the toxicity of THC delivered in any form, evidence supports the selective use of pure THC preparations to treat nausea associated with cancer chemotherapy and to stimulate appetite. The evidence does not support the reclassification of crude marijuana as a prescribable medicine.
Author and Article Information
From the International Drug Strategy Institute, Topeka, Kansas; University of Kansas School of Medicine, Kansas City, Kansas; and Fairfax Hospital, Falls Church, Virginia.
PERSPECTIVE
Medicinal Applications of Delta-9-Tetrahydrocannabinol and Marijuana
Acknowledgments: The authors thank the professional review committee of the International Drug Strategy Institute for review and helpful input and Lenora Kinsey for assistance with the literature search.
Requests for Reprints: Eric A. Voth, MD, The International Drug Strategy Institute, 901 Garfield, Topeka, KS 66606.
Current Author Addresses: Dr. Voth: The International Drug Strategy Institute, 901 Garfield, Topeka, KS 66606.
This article has been cited by other articles:
|
|
 |
|
  S. DeMorrow, S. Glaser, H. Francis, J. Venter, B. Vaculin, S. Vaculin, and G. Alpini Opposing Actions of Endocannabinoids on Cholangiocarcinoma Growth: RECRUITMENT OF Fas AND Fas LIGAND TO LIPID RAFTS J. Biol. Chem., April 27, 2007; 282(17): 13098 - 13113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Amtmann, P. Weydt, K. L. Johnson, M. P. Jensen, and G. T. Carter Survey of cannabis use in patients with amyotrophic lateral sclerosis American Journal of Hospice and Palliative Medicine, March 1, 2004; 21(2): 95 - 104. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Ruiu, G. A. Pinna, G. Marchese, J.-M. Mussinu, P. Saba, S. Tambaro, P. Casti, R. Vargiu, and L. Pani Synthesis and Characterization of NESS 0327: A Novel Putative Antagonist of the CB1 Cannabinoid Receptor J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 363 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-T. Samson, A. Small-Howard, L. M. N. Shimoda, M. Koblan-Huberson, A. J. Stokes, and H. Turner Differential Roles of CB1 and CB2 Cannabinoid Receptors in Mast Cells J. Immunol., May 15, 2003; 170(10): 4953 - 4962. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jatoi, H. E. Windschitl, C. L. Loprinzi, J. A. Sloan, S. R. Dakhil, J. A. Mailliard, S. Pundaleeka, C. G. Kardinal, T. R. Fitch, J. E. Krook, et al. Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study J. Clin. Oncol., January 15, 2002; 20(2): 567 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M Kinzbrunner Review: cannabinoids and codeine have similar effects on pain relief, but cannabinoids commonly cause psychotropic adverse effects Evid. Based Med., January 1, 2002; 7(1): 24 - 24. [Full Text] [PDF]
|
|
|
|
|
|
B. M Kinzbrunner Review: cannabinoids control chemotherapy-induced nausea and vomiting but increase the risk of side effects Evid. Based Med., January 1, 2002; 7(1): 25 - 25. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Sanchez, M. L. de Ceballos, T. G. del Pulgar, D. Rueda, C. Corbacho, G. Velasco, I. Galve-Roperh, J. W. Huffman, S. Ramon y Cajal, and M. Guzman Inhibition of Glioma Growth in Vivo by Selective Activation of the CB2 Cannabinoid Receptor Cancer Res., August 1, 2001; 61(15): 5784 - 5789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R Tramer, D. Carroll, F. A Campbell, D J. M Reynolds, R A. Moore, and H. J McQuay Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review BMJ, July 7, 2001; 323(7303): 16 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. T. Carter and B. S. Rosen Marijuana in the management of amyotrophic lateral sclerosis American Journal of Hospice and Palliative Medicine, July 1, 2001; 18(4): 264 - 270. [Abstract] [PDF]
|
|
|
|
 |
|
 C. L. Shapiro and A. Recht Side Effects of Adjuvant Treatment of Breast Cancer N. Engl. J. Med., June 28, 2001; 344(26): 1997 - 2008. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Sánchez, D. Rueda, B. Ségui, I. Galve-Roperh, T. Levade, and M. Guzmán The CB1 Cannabinoid Receptor of Astrocytes Is Coupled to Sphingomyelin Hydrolysis through the Adaptor Protein Fan Mol. Pharmacol., April 16, 2001; 59(5): 955 - 959. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. Disdier, B. Granel, J. Serratrice, J. Constans, U. Michon-Pasturel, E. Hachulla, C. Conri, B. Devulder, L. Swiader, P. Piquet, et al. Cannabis Arteritis Revisited: Ten New Case Reports Angiology, January 1, 2001; 52(1): 1 - 5. [Abstract] [PDF]
|
|
|
|
|
|
D. Rueda, I. Galve-Roperh, A. Haro, and M. Guzmán The CB1 Cannabinoid Receptor Is Coupled to the Activation of c-Jun N-Terminal Kinase Mol. Pharmacol., October 1, 2000; 58(4): 814 - 820. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. A. Voth, P. Sharpe, and G. Smith Cannabis Is Not Equivalent to Cannabinoids Response Anesth. Analg., August 1, 2000; 91(2): 496 - 496. [Full Text] [PDF]
|
|
|
|
|
|
L. X. Zhu, S. Sharma, M. Stolina, B. Gardner, M. D. Roth, D. P. Tashkin, and S. M. Dubinett {Delta}-9-Tetrahydrocannabinol Inhibits Antitumor Immunity by a CB2 Receptor-Mediated, Cytokine-Dependent Pathway J. Immunol., July 1, 2000; 165(1): 373 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Green Marijuana Smoking vs Cannabinoids for Glaucoma Therapy Arch Ophthalmol, November 1, 1998; 116(11): 1433 - 1437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C.-K. Chan, T. R. Hinds, S. Impey, and D. R. Storm Hippocampal Neurotoxicity of Delta 9-Tetrahydrocannabinol J. Neurosci., July 15, 1998; 18(14): 5322 - 5332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Derkinderen, M. Toutant, G. Kadare, C. Ledent, M. Parmentier, and J.-A. Girault Dual Role of Fyn in the Regulation of FAK+6,7 by Cannabinoids in Hippocampus J. Biol. Chem., October 5, 2001; 276(41): 38289 - 38296. [Abstract] [Full Text] [PDF]
|
|
Article
